No other planned concurrent investigational agents or other tumor directed therapy (chemotherapy, radiation) while on study
Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy; concurrent treatment with agents to prevent skeletal-related events (such as zoledronic acid or denosumab) will be allowed as long as it was initiated prior to study entry
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study
Concurrent use of other investigational agents
Patients may not receive any concurrent investigational agents while on study
Concurrent use of any other investigational agents
Patients who are receiving concurrent investigational therapy;
Concurrent administration of any other investigational agents
Subject receiving concurrent chemotherapeutics or investigational agents within 30 days of study entry, including gliadel wafers or gliasite application.
Concurrent administration of other cancer specific therapy or investigational agents during the course of this study is not allowed
Concurrent treatment with any other investigational therapeutic agents
No other concurrent chemotherapeutic or investigational agents for this cancer. However, concurrent glucocorticoids are allowed;
Concurrent therapy with other systemic anti-neoplastic or investigational agents
Receiving concurrent investigational therapy
No other concurrent investigational agents are allowed
Concurrent use of other investigational agents
Patients receiving concurrent investigational chemotherapeutic agents
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents).
Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy
DONOR: Receiving any investigational agents, or concurrent biological, chemotherapy, immunosuppression or radiation therapy
Patients receiving any concurrent investigational agents
Use of any other concurrent investigational agents or anticancer agents including hormonal therapy, except in the case of prostate cancer patients who are being treated anti-androgen or bone targeting therapies.
Concurrent use of restricted agents
Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy
Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy
Patients may not be receiving any other investigational agents, or concurrent parenteral biological, chemotherapy, or radiation therapy; oral chemotherapeutic agents or biologics - for example ruxolitinib therapy (either past or current exposure) - is allowed
Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Patients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapy
Concurrent use of other investigational agents or Optune™ device
Use of any other concurrent investigational agents or anticancer agents including hormonal therapy, except in the case of prostate cancer patients who are being treated with LHRH agonist at the time of trial entry
Concurrent use of any other investigational agents
Current or planned use of other investigational agents, or concurrent biological chemotherapy, or radiation therapy during the study treatment period
Current or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment period
Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; may have received an experimental agent prior to enrolling in the trial
Concurrent use of any other investigational agents
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
The use of other concurrent investigational agents will not be allowed
Concurrent use of other investigational agents
Concurrent use of any other investigational agents
Current or planned use of other investigational agents, or concurrent biological, chemotherapy, or radiation therapy during the study treatment period
Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Patients receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy
Concurrent administration of any other investigational agents
Patient is receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Concurrent treatment with other investigational agents is not permitted
Concurrent use of other investigational agents.
Patients may not receive any other concurrent investigational agents while on study
Concurrent treatment with other investigational agents
Concurrent usage of other investigational agents, chemotherapy, or hormone therapy; prior chemotherapy, hormonal therapy, targeted therapy, and investigational agents are allowed but all toxicities grade >= 2 must have resolved by the time of study commencement (except alopecia)
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) other than temozolomide
Concurrent anti-cancer therapy, including chemotherapy agents, targeted agents, or biological agents not otherwise specified in this protocol
Concurrent use of any other investigational agents.
Concurrent use of any other approved or investigational anticancer agents, including hormonal agents
Use of investigational agents or concurrent anti-cancer treatment within the last 4 weeks of registration
Other concurrent investigational agents;
Research participants receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Concurrent therapy with other investigational agents
Patients may not be receiving any other investigational agents, or concurrent biological chemotherapy
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
Concurrent treatment with other investigational or anti-neoplastic agents
Concurrent use of other investigational agents
ANY concurrent investigational agents
No concurrent methotrexate, thiotepa, cytarabine, or investigational agents
Concurrent use of other anti-cancer therapy including chemotherapy agents, targeted agents, or biological agents not otherwise specified in this protocol
Concurrent treatment with other investigational agents(s)
Patients may not be receiving any other experimental agents and/or any other concurrent anticancer agents or therapies except hormonal maintenance
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies
Use of any other concurrent investigational agents or anticancer agents except for hormonal therapy as outlined in inclusion criteria
Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents, radiation or immunotherapy) within 4 weeks of the first dose of the study drug
Concurrent use of any other investigational agents on a clinical trial
Is receiving any other concurrent systemic tumor therapy, including hormonal agents and HER-2 inhibitors
No other concurrent investigational agents
Patients who are receiving any other investigational agents with the intent to treat myeloma; permitted concurrent therapies include:\r\n* Bisphosphonates
No concurrent anti-cancer treatment (including topical agents such as imiquimod) or investigational agents
Patient has concurrent use of anti-neoplastic agents including investigational therapy
Patient is receiving concurrent treatment with other investigational agents not allowed as part of the combination regimen in the parental study protocol.
Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies except hormonal maintenance treatment for prostate cancer
Concurrent use of investigational agents
Actively receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy
Concurrent therapy with investigational agents
Concurrent systemic therapy for prostate cancer with investigational agents.
Concurrent use of other anti-cancer therapy, including chemotherapy agents, targeted agents, biological agents, immunotherapy, or investigational agents not otherwise specified in this protocol